BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024 07:45 ET
|
BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
GeoVax Announces Multiple Patent Issuances and Allowances
February 13, 2024 09:00 ET
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
January 04, 2024 08:00 ET
|
Enara bio
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicityBoehringer...
Cancer Vaccine Market Size Worth USD 21.39 Billion in 2032 | Emergen Research
January 02, 2024 08:03 ET
|
Emergen Research
Vancouver, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The global cancer vaccine market demonstrated a robust USD 7.31 Billion in 2022, with expectations of a substantial CAGR of 10.9% throughout the forecast...
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
December 18, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled...
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
November 28, 2023 08:27 ET
|
Evaxion Biotech
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a novel class of antigensBroad Applicability –...
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023 10:12 ET
|
Evaxion Biotech
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor...
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 06, 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023 11:15 ET
|
Evaxion Biotech
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with...
Cancer Vaccine Market Anticipates 11.8% CAGR Fueled by Government Funding and Research Initiatives - Marketresearch.biz Study
October 23, 2023 06:50 ET
|
MarketResearch.biz
New York, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The cancer vaccine market is expected to witness growth with an estimated increase from US$ 6.8 Billion in 2022 to around US$ 20.2 Billion by the year...